Australia Patient Derived Xenografts/PDX Models Market (2025-2030)
The Australia Patient Derived Xenografts/PDX Models Market was valued at $2.6 Million in 2025 and projected to reach to $4.1 Million by 2030, representing a compound annual growth rate of 9.0%. Australia's PDX models market is positioned for sustained growth as the country strengthens its role in personalized medicine research.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Australia Patient Derived Xenografts/PDX Models Market Trends and Insights
- Australia is establishing itself as a key player in personalized medicine research within the Asia Pacific region, driven by increasing investment in oncology research and precision therapeutics.
- The market in Australia reflects growing adoption of PDX models among research institutions and biopharmaceutical companies seeking advanced preclinical testing platforms. The 9.0% compound annual growth rate (CAGR) through 2030 demonstrates Australia's commitment to advancing cancer research infrastructure and drug development capabilities.
- Australia's market growth is supported by collaborations between academic medical centers, government funding initiatives, and private sector investment in translational research.
- The expansion of PDX model applications in Australia underscores the country's role in supporting global pharmaceutical development and personalized oncology treatment strategies..
Key Market Statistics
- CAGR (2025-2030) 9.0% CAGR
- Market Size, 2025 ~USD 2.6 Million
- Forecast, 2030 ~USD 4.1 Million
- Country Australia
Australia Patient Derived Xenografts/PDX Models Market Overview
Market Valuation Growth :
Australia's PDX models market is valued at $2.6 million in 2025, with a projected CAGR of 9% through 2030, reaching $4.1 million. This steady growth trajectory reflects increasing adoption of personalized medicine approaches in Australian research institutions.
Asia Pacific Leadership Position :
Australia is emerging as a key regional hub for PDX model development and oncology research within Asia Pacific. The country's advanced research infrastructure and regulatory framework position it as a preferred location for precision therapeutics development and clinical validation studies.
Oncology Research Investment :
Significant investment in Australian oncology research programs is driving PDX model adoption. Major research centers and pharmaceutical companies are expanding their precision medicine capabilities, creating strong demand for patient-derived xenograft models in drug development pipelines.
Personalized Medicine Expansion :
Australia's healthcare sector is increasingly embracing personalized medicine and precision therapeutics. This shift is accelerating the integration of PDX models into clinical research workflows, supporting the development of targeted cancer treatments tailored to individual patient profiles.
Australia Patient Derived Xenografts/PDX Models Market Dynamics
- With a 9% CAGR through 2030, the market will benefit from expanding oncology research initiatives, increased pharmaceutical R&D investments, and growing collaboration between academic institutions and biotech companies.
- The Australian government's support for precision medicine infrastructure and clinical research advancement will further accelerate market expansion. The competitive landscape in Australia is characterized by increasing partnerships between local research organizations and global pharmaceutical companies seeking to leverage PDX models for drug development.
- As healthcare providers and research institutions prioritize precision therapeutics, demand for high-quality patient-derived xenograft models will continue to rise, positioning Australia as a significant contributor to the broader Asia Pacific PDX market..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Australia's PDX models market is valued at $2.6 million in 2025 and is forecast to reach $4.1 million by 2030, representing a 9.0% CAGR.
- Australia is leveraging PDX technology to strengthen its position in personalized oncology research and precision medicine development.
- Growth in Australia is driven by increased collaboration between academic institutions, government funding, and biopharmaceutical companies investing in translational research.
- Australia's expanding PDX market reflects the country's strategic focus on supporting global drug development and advancing cancer treatment innovation.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
Australia Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 0.69 | 0.75 | 0.82 | 0.89 | 0.97 | 1.05 | 1.14 | 1.23 | 8.6 |
| CROS & CDMOS | 0.45 | 0.48 | 0.53 | 0.58 | 0.62 | 0.67 | 0.73 | 0.78 | 8.2 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 1.43 | 1.58 | 1.74 | 1.92 | 2.1 | 2.3 | 2.51 | 2.74 | 9.5 |
| TOTAL | 2.57 | 2.81 | 3.08 | 3.39 | 3.7 | 4.03 | 4.38 | 4.76 | 9.1 |
Target Audience
- Pharmaceutical Companies : Australian and international pharma firms need market intelligence to guide R&D investments in PDX-based drug development programs, identify local research partnerships, and optimize clinical trial strategies within Australia's precision medicine ecosystem.
- Biotech and CRO Organizations : Contract research organizations and biotech companies require detailed market data to assess opportunities for establishing PDX model services in Australia, understand competitive positioning, and identify potential client bases among local research institutions.
- Research Institutions and Universities : Australian academic medical centers and research organizations need market insights to justify PDX model investments, benchmark capabilities against peers, secure funding for precision medicine initiatives, and identify collaboration opportunities with industry partners.
- Healthcare Investors and Venture Capital : Investment firms evaluating opportunities in Australian precision medicine and biotech sectors require comprehensive market data to assess growth potential, identify promising companies and technologies, and make informed funding decisions in the PDX space.
- Government and Policy Makers : Australian health authorities and research funding bodies need market analysis to inform policy decisions, allocate research funding effectively, support precision medicine infrastructure development, and position Australia competitively in the global PDX market.
Key Companies in the Australia Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Reasons to Buy this Report
- Market-Specific Growth Insights : Gain detailed understanding of Australia's unique PDX market dynamics, including local investment trends, regulatory environment, and growth drivers specific to the Australian healthcare and research landscape through 2030.
- Competitive Positioning Strategy : Identify opportunities to establish or expand operations in Australia's emerging PDX market. Understand local research partnerships, institutional players, and market gaps to develop targeted entry or expansion strategies in this high-growth region.
- Investment Decision Support : Make informed investment decisions with comprehensive market sizing, CAGR analysis, and forecast data specific to Australia. Evaluate the market's growth potential relative to global trends and assess ROI opportunities in Australian precision medicine research.
- Regulatory and Operational Guidance : Navigate Australia's specific regulatory requirements, research infrastructure, and operational considerations for PDX model development and commercialization. Understand local compliance frameworks and institutional requirements for market success.
- Partnership and Collaboration Opportunities : Identify key research institutions, pharmaceutical companies, and biotech organizations operating in Australia's PDX market. Develop strategic partnerships and collaboration frameworks to accelerate market penetration and product adoption in the region.
Frequently asked questions
What is the current market size of PDX models in Australia?
Australia's Patient Derived Xenografts market was valued at $2.6 million in 2025 and is expected to grow to $4.1 million by 2030.
What is the projected growth rate for Australia's PDX models market?
Australia's PDX models market is projected to grow at a compound annual growth rate (CAGR) of 9.0% from 2025 to 2030.
What factors are driving PDX market growth in Australia?
Growth in Australia is driven by increased investment in oncology research, collaborations between academic and private sectors, government funding initiatives, and rising demand for personalized medicine platforms.
How does Australia's PDX market compare to the global market?
Australia's 9.0% CAGR is lower than the global 12.5% CAGR, reflecting the country's emerging but growing role in the PDX models market within the Asia Pacific region.
Which sectors are driving PDX adoption in Australia?
Australia's PDX market is driven by biopharmaceutical companies, academic research institutions, cancer research centers, and contract research organizations focused on precision oncology and drug development.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report